Axel Hoos

Axel Hoos has extensive experience in oncology and immunology, currently serving as the Chief Executive Officer at Scorpion Therapeutics since July 2021 and also as a Director on the Board of Directors for NextPoint Therapeutics, Inc. since March 2023. Previously, Axel held multiple senior positions at GSK, including Senior Vice President for R&D Governance in Oncology, and contributed to various organizations as a member and executive chairman of the Board of Trustees at the Sabin Vaccine Institute and as Co-Director of the Cancer Immunotherapy Consortium at the Cancer Research Institute. With a notable background in clinical development and leadership roles at companies such as TCR² Therapeutics Inc. and Imugene Limited, Axel has also contributed to the field through educational endeavors, holding degrees from esteemed institutions including Heidelberg University and the Technical University of Munich.